Monday, April 27, 2009 2:27:25 PM
HGSI -
added to LONGTIME-portfolio @ 1,19€
did additional dd...
IMO (could become a MONSTER)
http://www.hgsi.com/
Three Products in Late-Stage Development
We now have three promising products in late-stage development, moving toward commercialization. We have reported the positive results of two Phase 3 trials of Albuferon®, and we plan to file global marketing applications in fall 2009. Two Phase 3 trials are ongoing for LymphoStat-B® in patients with lupus, with results expected in July and November 2009. We are developing both of these products in collaboration with world leaders in the pharmaceutical industry. Also in late-stage development is ABthrax™, which offers a new way to address the threat of inhalation anthrax and is being developed under a contract with the U.S. Government.
High-Potential Pipeline
Right behind these late-stage products is an emerging, high-potential mid-stage pipeline, led by our TRAIL receptor antibodies for cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
---------------------------------------------------------------
http://www.hgsi.com/products.html
CLINICAL DEVELOPMENT PIPELINE
HGS has a well balanced and deep portfolio of novel drugs directed toward diseases that represent significant unmet medical need. Three of these products are in late-stage development.
In March 2009 and December 2008, we reported positive Phase 3 results from our Phase 3 trials of Albuferon® (albinterferon alfa-2b) in patients with chronic hepatitis C. Filings of global marketing applications are planned in fall 2009. Two Phase 3 trials are ongoing for LymphoStat-B® (belimumab) in patients with systemic lupus erythematosus (SLE), with results expected in July and November 2009. ABthrax™ (raxibacumab) is in late-stage development for the treatment of inhalation anthrax.
Right behind these late-stage products is an emerging high-potential mid-stage pipeline, led by our anti-cancer products, HGS-ETR1 (mapatumumab) and HGS 1029, an IAP inhibitor – both for the treatment of cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
---------------------------------------------------------------
Q4/2008 QUARTERLY RESULT
http://www.hgsi.com/quarterly-results/human-genome-sciences-announces-fourth-quarter-and-full-year-2008-financial-results-and-key-develop.html
added to LONGTIME-portfolio @ 1,19€
did additional dd...
IMO (could become a MONSTER)
http://www.hgsi.com/
Three Products in Late-Stage Development
We now have three promising products in late-stage development, moving toward commercialization. We have reported the positive results of two Phase 3 trials of Albuferon®, and we plan to file global marketing applications in fall 2009. Two Phase 3 trials are ongoing for LymphoStat-B® in patients with lupus, with results expected in July and November 2009. We are developing both of these products in collaboration with world leaders in the pharmaceutical industry. Also in late-stage development is ABthrax™, which offers a new way to address the threat of inhalation anthrax and is being developed under a contract with the U.S. Government.
High-Potential Pipeline
Right behind these late-stage products is an emerging, high-potential mid-stage pipeline, led by our TRAIL receptor antibodies for cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
---------------------------------------------------------------
http://www.hgsi.com/products.html
CLINICAL DEVELOPMENT PIPELINE
HGS has a well balanced and deep portfolio of novel drugs directed toward diseases that represent significant unmet medical need. Three of these products are in late-stage development.
In March 2009 and December 2008, we reported positive Phase 3 results from our Phase 3 trials of Albuferon® (albinterferon alfa-2b) in patients with chronic hepatitis C. Filings of global marketing applications are planned in fall 2009. Two Phase 3 trials are ongoing for LymphoStat-B® (belimumab) in patients with systemic lupus erythematosus (SLE), with results expected in July and November 2009. ABthrax™ (raxibacumab) is in late-stage development for the treatment of inhalation anthrax.
Right behind these late-stage products is an emerging high-potential mid-stage pipeline, led by our anti-cancer products, HGS-ETR1 (mapatumumab) and HGS 1029, an IAP inhibitor – both for the treatment of cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
---------------------------------------------------------------
Q4/2008 QUARTERLY RESULT
http://www.hgsi.com/quarterly-results/human-genome-sciences-announces-fourth-quarter-and-full-year-2008-financial-results-and-key-develop.html
posts are IMHO // either news - with LINK
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
